Home » Stocks » ACET

Adicet Bio, Inc. (ACET)

Stock Price: $13.10 USD -0.32 (-2.38%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $13.44 +0.34 (2.60%) Jan 15, 4:39 PM
Market Cap 257.14M
Revenue (ttm) 3.03M
Net Income (ttm) -56.31M
Shares Out 5.21M
EPS (ttm) -1.90
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $13.10
Previous Close $13.42
Change ($) -0.32
Change (%) -2.38%
Day's Open 13.40
Day's Range 2.28 - 13.44
Day's Volume 25,695
52-Week Range 0.87 - 21.40

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

MENLO PARK, Calif. and BOSTON, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cel...

Seeking Alpha - 2 weeks ago

Adicet Bio is a biotechnology company concentrated on developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet has developed a pre-clinical pipeline of 4 therap...

Zacks Investment Research - 1 month ago

Adicet Bio (ACET) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

GlobeNewsWire - 1 month ago

MENLO PARK, Calif., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies...

GlobeNewsWire - 1 month ago

MENLO PARK, Calif. and BOSTON, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cel...

GlobeNewsWire - 2 months ago

MENLO PARK, Calif. and BOSTON, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cel...

GlobeNewsWire - 2 months ago

MENLO PARK, Calif. and BOSTON, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cel...

GlobeNewsWire - 2 months ago

MENLO PARK, Calif. and BOSTON, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cel...

GlobeNewsWire - 2 months ago

Phase 1 Clinical Study will Evaluate ADI-001 Safety and Efficacy in Patients with B-cell non-Hodgkin's lymphoma Phase 1 Clinical Study will Evaluate ADI-001 Safety and Efficacy in Patients wit...

GlobeNewsWire - 3 months ago

MENLO PARK, Calif. and BOSTON, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for...

GlobeNewsWire - 3 months ago

MENLO PARK, Calif. and BOSTON, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies ...

GlobeNewsWire - 3 months ago

MENLO PARK, Calif. and BOSTON, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell...

GlobeNewsWire - 3 months ago

MENLO PARK, Calif. and BOSTON, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell...

GlobeNewsWire - 4 months ago

MENLO PARK, Calif. and BOSTON, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq:  ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies...

GlobeNewsWire - 4 months ago

MENLO PARK, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq:  ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer...

GlobeNewsWire - 4 months ago

- Adicet Emerges as a Leading Allogeneic Gamma Delta T Cell Therapy Company Focused on Oncology -

GlobeNewsWire - 5 months ago

BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to preve...

PRNewsWire - 5 months ago

NEW YORK, July 28, 2020 /PRNewswire/ -- TrialSpark, a tech-enabled drug development partner committed to improving the speed, quality, and innovation of clinical trials, today announced a coll...

GlobeNewsWire - 5 months ago

BOSTON, July 28, 2020 (GLOBE NEWSWIRE) -- resTORbio resTORbio, Inc. (Nasdaq: TORC) today announced the award from the National Institute on Aging to fund a randomized, double-blind, placebo-...

PRNewsWire - 6 months ago

NEW YORK, June 29, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of resTORbio, Inc. ("TORC" or th...

Seeking Alpha - 8 months ago

ResTORbio's Reverse Merger With Adicet Should Unlock Substantial Value For Shareholders

GlobeNewsWire - 8 months ago

BOSTON, April 30, 2020 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC) today announced that due to the public health impact of the coronavirus pandemic and to prioritize the health and we...

GlobeNewsWire - 9 months ago

BOSTON, April 03, 2020 (GLOBE NEWSWIRE) -- resTORbio (Nasdaq: TORC) today announced that it will postpone enrollment in the fifth cohort of its ongoing Phase 1b/2a trial of RTB101, an orally...

Seeking Alpha - 1 year ago

ResTORbio Is Trading At Less Than Half Of Its Net Cash After Crash

The Motley Fool - 1 year ago

The company's lead drug candidate flopped an important clinical trial, which has investors questioning the validity of the pipeline's approach.

24/7 Wall Street - 1 year ago

There is a huge risk-reward factor in emerging pharmaceutical and biotech companies that happen to have all their eggs in just one basket.

GlobeNewsWire - 1 year ago

Analysis indicates RTB101 upregulates innate antiviral immunity to prevent clinically symptomatic respiratory illnesses caused by multiple viruses in older adults Analysis indicates RTB101 upr...

GlobeNewsWire - 1 year ago

BOSTON, Sept. 23, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc., (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to pre...

Seeking Alpha - 1 year ago

TORC has done tolerably well since IPO-ing last year, producing solid phase 2 results from lead drug candidate RTB101.

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in resTORbio.

About ACET

Adicet Bio, a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors or T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. Its products pipeline includes ADI-001, which is in Phase 1 clinical study to treat non-Hodgkin's lymphoma; and ADI-002 that is in Phase 1 clinical... [Read more...]

Industry
Medicinal and Botanical Manufacturing
Founded
1947
CEO
Chen Schor
Country
United States
Stock Exchange
NASDAQ
Ticker Symbol
ACET
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Adicet Bio stock is "Strong Buy." The 12-month stock price forecast is 28.25, which is an increase of 115.65% from the latest price.

Price Target
$28.25
(115.65% upside)
Analyst Consensus: Strong Buy